Garner Elizabeth I O, Lipson Elizabeth, Bernstein Marilyn R, Goldstein Donald P, Berkowitz Ross S
New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J Reprod Med. 2002 May;47(5):380-6.
Modern therapy for molar pregnancy and gestational trophoblastic tumors has resulted in high cure rates and preservation of fertility, even in the setting of metastatic disease requiring chemotherapy. Patients and their partners facing future pregnancy after treatment for gestational trophoblastic disease express fear related to risk of disease recurrence and outcome of subsequent pregnancies. Data from the New England Trophoblastic Disease Center on later pregnancies following complete and partial mole as well as persistent gestational trophoblastic tumor show that patients, in general, can anticipate normal subsequent pregnancy outcomes.
现代针对葡萄胎和妊娠滋养细胞肿瘤的治疗方法已带来了高治愈率,并保留了生育能力,即使是在需要化疗的转移性疾病情况下也是如此。接受妊娠滋养细胞疾病治疗后面临未来妊娠的患者及其伴侣表达了与疾病复发风险和后续妊娠结局相关的担忧。来自新英格兰滋养细胞疾病中心关于完全性和部分性葡萄胎以及持续性妊娠滋养细胞肿瘤后后续妊娠的数据表明,总体而言,患者可以预期正常的后续妊娠结局。